OncoGenerix

History

2024: Partnership with RDIF and N.F. Gamalei National Research Institute

On May 15, 2024, the Russian Direct Investment Fund (RDIF) announced a partnership with the Chinese company OncoGenerix, which has production facilities for the production of injectable drugs, with the aim of transferring technologies and production in China of a number of vaccines developed by the N.F. Gamalei.

OncoGenerix offers a fully integrated set of contract manufacturing services including technical transfer, process development, scaling, equipment and process validation, formulation, packaging, lyophilization, inspection, labeling and packaging to the highest industry standards. According to the agreements reached, N.F. Gamalei will have the opportunity to open a research and development center in China, which will allow developers to adapt drugs and additional research on the spot.

The portfolio of manufactured drugs will be determined based on the analysis of the most popular areas of therapy. If necessary, other partners in the Chinese market can be involved in the process of vaccine production and supply.

RDIF played a key role financing in the international promotion of vaccines against " coronavirus and"Sputnik V " , "which Satellite Light were developed by the N.F. Gamalei. These vaccines have become the most exported pharmaceutical drugs in history: RUSSIAN FEDERATION Sputnik V was delivered to more than 70 countries with a population of over 4 billion people, Sputnik Light - to more than 30 countries. RDIF's experience in establishing the production and distribution of Sputnik vaccines made it possible to create a basis for interaction with partners in the field around the health care world.

{{quote 'author = said Kirill Dmitriyev, CEO of the Russian Direct Investment Fund (RDIF). | Vaccines against coronavirus "Sputnik V" and "Sputnik Light," developed by NICEM named after N.F. Gamalei, saved millions of lives around the world during a pandemic. Safe and effective Russian drugs withstood competition with giants of the pharmaceutical industry and at the same time did not demonstrate serious adverse events, won the trust of specialists and ordinary people. The partnership between RDIF and OncoGenerix opens up an opportunity to bring to the Chinese market and other developments of the Gamaleya Center, which have already proven themselves in Russia and have significant export potential,}}